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Risk Factors for Optic Disc Hemorrhage in the
Low-Pressure Glaucoma Treatment Study
RAFAEL L. FURLANETTO, CARLOS GUSTAVO DE MORAES, CHRISTOPHER C. TENG, JEFFREY M. LIEBMANN,
DAVID S. GREENFIELD, STUART K. GARDINER, ROBERT RITCH, AND THEODORE KRUPIN, FOR THE
LOW-PRESSURE GLAUCOMA TREATMENT STUDY GROUP PURPOSE: To investigate risk factors for disc hemor-
rhage detection in the Low-Pressure Glaucoma Treat-
ment Study.
 DESIGN: Cohort of a randomized, double-masked,
multicenter clinical trial.
 METHODS: Low-Pressure Glaucoma Treatment Study
patients with at least 16 months of follow-up were
included. Exclusion criteria included untreated intraoc-
ular pressure (IOP) of more than 21 mm Hg, visual field
mean deviation worse thanL16 dB, or contraindications
to study medications. Patients were randomized to topical
treatment with timolol 0.5% or brimonidine 0.2%. Ster-
eophotographs were reviewed independently by 2 masked
graders searching for disc hemorrhages. The main out-
comes investigated were the detection of disc hemorrhage
at any time during follow-up and their recurrence. Ocular
and systemic risk factors for disc hemorrhage detection
were analyzed using the Cox proportional hazards model
and were tested further for independence in amultivariate
model.
 RESULTS: Two hundred fifty-three eyes of 127 subjects
(mean age, 64.7 ± 10.9 years; women, 58%; European
ancestry, 71%) followed up for an average ± standard
deviation of 40.6 ± 12 months were included. In the
multivariate analysis, history of migraine (hazard ratio
[HR], 5.737;P[ .012), narrower neuroretinal rimwidth
at baseline (HR, 2.91; P [ .048), use of systemic
b-blockers (HR, 5.585; P [ .036), low mean systolic
blood pressure (HR,1.06;P[ .02), and lowmeanarterial
ocular perfusion pressure during follow-up (HR, 1.172;
P[ .007) were significant and independent risk factors
for disc hemorrhage detection. Treatment randomizationAccepted for publication Feb 2, 2014.
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 2014 BY ELSEVIER INC.was not associated with either the occurrence or recur-
rence of disc hemorrhages.
 CONCLUSIONS: In this cohort of Low-Pressure Glau-
coma Treatment Study patients, migraine, baseline
narrower neuroretinal rim width, low systolic blood pres-
sure and mean arterial ocular perfusion pressure, and use
of systemic b-blockers were risk factors for disc hemor-
rhage detection. Randomization assignment did not influ-
ence the frequency of disc hemorrhage detection. (Am
J Ophthalmol 2014;157:945–952.  2014 by Elsevier
Inc. All rights reserved.)
G
LAUCOMA IS A DEGENERATIVE OPTIC NEUROPA-
thy characterized by progressive loss of retinal
ganglion cells and their axons, resulting in char-
acteristic optic disc changes and visual field (VF) loss.1,2
Although elevated intraocular pressure (IOP) is the most
important known risk factor for onset and progression,3–7
glaucoma develops in a sizable subset of patients despite
untreated IOP within the statistically defined normal
range.8–11 Low-pressure glaucoma is a term used to
describe that segment of patients with primary open-
angle glaucoma whose untreated IOPs are always 21 mm
Hg or less by Goldmann applanation tonometry.8
The Low-Pressure Glaucoma Treatment Study12–15 was
a multicenter, double-masked, prospective, randomized
clinical trial that investigated VF outcomes in low-
pressure glaucoma patients treated either with a topical
b-adrenergic antagonist (timolol maleate 0.5%) or an a2-
adrenergic agonist (brimonidine tartrate 0.2%). The sub-
jects randomized to topical brimonidine 0.2% were less
prone to have VF progression than those treated with
timolol 0.5%, despite similar IOP levels during the
follow-up period.14 However, the explanation for this
outcome remains unclear, and a possible neuroprotective
effect of brimonidine 0.2%, a detrimental effect of timolol
0.5%, or both were hypothesized.14,15
Disc hemorrhage is a feature of glaucomatous optic neu-
ropathy commonly observed in low-pressure glaucoma and
rarely found in normal eyes.16–21 The association between
glaucoma and disc hemorrhage was reported first by
Bjerrum in 1889,22 and after the seminal work by Drance
and Begg in 1970,16 it became the subject of numerous
publications.17–21,23–30 Characterized by splinter-like or
flame-shaped hemorrhage at or adjacent to the optic nerve945ALL RIGHTS RESERVED.
head, disc hemorrhage is an important risk factor for
the onset25 and progression26–29 of glaucomatous optic
neuropathy, particularly in low-pressure glaucoma.30,31
Given that the pathogenesis of disc hemorrhage has not
yet been elucidated completely, recognition of the risk
factors associated with disc hemorrhage may contribute
to our understanding of the mechanisms involved in its
occurrence. Based on the Low-Pressure Glaucoma Treat-
ment Study findings,14,15 we hypothesized that among
these risk factors, medical treatment with timolol 0.5%
may be associated with a higher rate of disc hemorrhage
occurrence than brimonidine 0.2%.
In the present study, we investigated the baseline and
intercurrent risk factors associated with disc hemorrhage
onset and recurrence among participants enrolled in the
Low-Pressure Glaucoma Treatment Study. In addition,
we investigated whether randomization to timolol maleate
0.5% or brimonidine tartrate 0.2% influenced the rate of
disc hemorrhage occurrence.METHODS
THE METHODOLOGY OF THE LOW-PRESSURE GLAUCOMA
TreatmentStudy, including baseline characteristics and study
design, have been described in detail elsewhere.12 In brief, the
study was a multicenter, prospective clinical trial in which
patients were randomized to treatment with topical brimoni-
dine tartrate 0.2% versus timolol maleate 0.5%. The institu-
tional review boards at all 13 participating centers approved
the study protocol, and informed consent was obtained from
all participants enrolled in the Low-Pressure Glaucoma
Treatment Study. The study was registered in the clinical tri-
als registry of the United States National Institutes of Health
(http://www.clinicaltrials.gov; no. NCT00317577).
 INCLUSION AND EXCLUSION CRITERIA: Study patients
had a diagnosis of low-pressure glaucoma that fulfilled the
following eligibility criteria: all known daytime untreated
IOP of 21 mm Hg or less, open iridocorneal angles, at least
2 reproducible VFs with glaucomatous defects in 1 or both
eyes on standard automated perimetry (Humphrey Field
Analyzer; Carl Zeiss Meditec, Inc, Dublin, California,
USA), with the location of the defect being consistent
with the photographic appearance of the optic nerve
head, and age of 30 years or older. To determine eligibility
based on IOP, all patients receiving IOP-lowering treat-
ment underwent a 4-week washout without therapy. Base-
line IOP (measured with a calibrated Goldmann
applanation tonometer) had to be 21 mm Hg or less in
both eyes with less than a 5-mm Hg difference between
the eyes on an office diurnal curve (8:00 AM, 10:00 AM,
noon, 4:00 PM) assessed before randomization.
Ocular exclusion criteria included the following: a history
of IOP of more than 21 mm Hg in the patient record,946 AMERICAN JOURNAL OFbest-corrected visual acuity worse than 20/40 in either eye,
a history of angle closure or an occludable angle by gonio-
scopy, prior glaucoma incisional surgery, inflammatory eye
disease, prior ocular trauma, diabetic retinopathy or other
diseases capable of causing VF loss or optic nerve deteriora-
tion, extensive glaucomatous VF damage with a mean
deviation worse than 16 decibels (dB), or a clinically
determined threat to central fixation in either eye. Systemic
exclusion criteria included a resting pulse of fewer than 50
beats/minute, severe or uncontrolled cardiovascular, renal,
or pulmonary disease that would preclude safe administra-
tion of a topical b-adrenergic antagonist (b-blocker), and
a prior myocardial infarction or stroke. Since the number
of visits (and hence number of optic disc stereophotographs)
influences the rate of disc hemorrhage detection,16,17 and to
minimize the confounding effect of higher dropout rates in
the brimonidine group, only those eyes with at least
16 months of follow-up were included in the analyses.
 RANDOMIZATION,TREATMENT,ANDMASKING: Patients
were assigned randomly to receive monotherapy with either
brimonidine tartrate 0.2% (Alphagan; Allergan, Inc, Irvine,
California, USA) or timolol maleate 0.5% (Timoptic; Merck
& Co, Inc, West Point, Pennsylvania, USA) twice daily in
both eyes, including the morning before each visit. To allow
for higher patient attrition in the brimonidine group attribut-
able to an expected rate of adverse events of approximately
20%,32,33 randomization and delivery of medications
(provided by Allergan, Inc) to the sites were stratified in
blocks of 7 (4 to brimonidine and to 3 timolol). The
randomization list was maintained, and masked study
medications were provided in new 10-mL white bottles
labeled with the assigned randomization number directly to
the clinical centers by an independent pharmacy (Fountain
Valley Cancer Center Pharmacy, Fountain Valley, Califor-
nia, USA). Ocular treatment other than the study medica-
tion was not permitted. Investigators, patients, and the VF
and optic disc reading centers were all masked to patient
assignment.
End points requiring discontinuation from the study
included: treated IOP of more than 21 mm Hg that was
confirmed within 1 month, safety concern as judged by
the treating physician, symptomatic ocular allergic adverse
events (hyperemia, pruritus, stinging, conjunctival follicu-
losis, or a combination thereof) requiring medication cessa-
tion, retinal events that could alter visual acuity or VF
(e.g., age-related macular degeneration), the occurrence
of systemic (e.g., respiratory or cardiovascular) adverse
events that prevented the administration of topical
timolol, nonocular intolerable events associated with
topical brimonidine (e.g., xerostomia, fatigue, drowsiness),
or if the patient moved or declined to continue participa-
tion. Data collection from discontinued patients ceased
at their final study visit. Data up to this point were included
in the analysis, but discontinued patients were no longer
followed up as part of the study.MAY 2014OPHTHALMOLOGY
 STUDY VISITS: Patients were examined at 1 and
4 months after initiation of treatment. Subsequent visits
were at 4-month (62 weeks) intervals. Prerandomization
and postrandomization morning visits recorded the
following: ocular and systemic history, blood pressure,
pulse, corrected visual acuity, IOP, slit-lamp examination
results, and optic disc evaluation for cup-to-disc ratio,
neuroretinal rim characteristics, and the presence of disc
hemorrhage. Gonioscopy and stereoscopic optic disc pho-
tographs were performed annually. Full-threshold standard
achromatic perimetry (Humphrey 24-2) VF was performed
at 4-month intervals according to protocol guidelines.
 OUTCOMEMEASURES: A disc hemorrhage was defined as
a splinter- or flame-shaped hemorrhage adjacent to the optic
disc border, on or within the retinal nerve fiber layer or
neuroretinal rim. If peripheral to the disc margin, it needed
to be contiguouswith theb-zoneparapapillary atrophywhen
this feature was present.28 Themain outcomemeasures were
(1) the detection of disc hemorrhage at any time during
follow-up (occurrence) and (2) the reappearance of disc
hemorrhage during follow-up in eyes with a prior disc hem-
orrhage after resolutionof the initial disc hemorrhage (recur-
rence). Stereophotographs were reviewed independently by
2 glaucoma specialists (D.S.G., J.M.L.) searching for disc
hemorrhages, and in cases of disagreement, a consensus
between examiners was required for adjudication.
We examined clinical characteristics that predicted the
occurrence of disc hemorrhage. The following demographic
and ocular parameters were investigated: age at baseline,
sex, family history of glaucoma, central corneal thickness,
cup-to-disc ratio (estimated during slit-lamp funduscopic
examination), refractive error spherical equivalent, and
lens status. Prerandomization data collected and investi-
gated for risk assessment were: IOP mean, peak, and fluctu-
ation during the diurnal curve; baseline pulse frequency;
baseline systolic and diastolic blood pressures; presence of
systemic comorbidities (migraine, Raynaud phenomenon,
systemic hypertension, and diabetes mellitus); and use of
systemicmedications (categorized as systemic antihyperten-
sives, systemic b-blockers, and antidiabetic agents). Post-
randomization variables consisted of series length (ie,
follow-up time); detection of at least 1 disc hemorrhage
on stereophotographs any time during follow-up; mean,
peak, and fluctuation of IOP; and blood pressure during
follow-up. For numerical variables, the mean was calculated
by averaging all values recorded during the follow-up
period. Fluctuation was defined as the standard deviation
of all measurements in the same interval. Mean ocular arte-
rial perfusion pressure was estimated by the equation34:
Mean arterial ocular perfusion pressure
¼ 2=3 3 ½diastolic blood pressure
þ 1=3 3 ðsystolic blood pressure
 diastolic blood pressureÞ  IOPVOL. 157, NO. 5 DISC HEMORRHAGE IN LOWData on systemic comorbidities and medications were
obtained from participants’ self-report.
 STATISTICAL ANALYSIS: Descriptive statistics are
presented with frequency tables and graphs, whereas esti-
mates of center and dispersion are described as mean and
standard deviation, respectively. If eligible, both eyes
of the same patient were included in the analyses. A
Cox proportional hazards model was used to test the
relationship between predictors and the outcome (disc
hemorrhage in either eye: yes or no), accounting for dif-
ferences in follow-up duration. First, a univariate model
independently testing each predictor was constructed
using the aforementioned clinical variables. Variables
with P < .25 in the univariate analysis were entered in
the multivariate analysis, along with other predictors pre-
viously reported as being associated significantly with disc
hemorrhage detection.23,27,35,36 Because mean arterial
ocular perfusion pressure, systolic blood pressure, and
diastolic blood pressure are correlated variables, they
should not be entered together in the same multivariate
model (ie, colinearity).37 Therefore, 2 different multivar-
iate models were performed using a backward elimination
approach based on the Wald test: one model that
included the blood pressure parameters (model 1) and
the other including mean arterial ocular perfusion pres-
sure (model 2). Computerized statistical analyses were
performed using SPSS for Windows version 16.1 (IBM
SPSS Statistics, Inc, Armonk, New York, USA), and
the a level was set at 0.05 (2-sided).RESULTS
OF 193 PATIENTS ASSESSED FOR ELIGIBILITY IN THE LOW-
Pressure Glaucoma Treatment Study, 178 were randomized
to treatment with either timolol or brimonidine. The char-
acteristics of the study population have been described in
detail elsewhere.12–15 Of those, 253 eyes of 127 subjects
(mean age, 64.7 6 10.9 years; women, 58%; European
ancestry, 71%) met the inclusion and exclusion criteria
for this study (at least 16 months of follow-up) and were
followed up, on average, for 40.6 6 12 months. Therefore,
the following results refer to this subset of participants (127
patients; 253 eyes), whose clinical characteristics have
been published previously.15
A total of 18 (7.1%) of 253 eyes of 15 (11.8%) of 127
patients experienced at least 1 disc hemorrhage during
follow-up. Three patients (20%) had disc hemorrhages
in both eyes (2 in the timolol group and 1 in the brimo-
nidine group). Five eyes (27.8%) had a single disc hemor-
rhage event, 4 eyes (22.2%) had 2 disc hemorrhages, 2
eyes (11.1%) had 3 disc hemorrhages, and 7 eyes
(38.9%) had 4 or more disc hemorrhages. With regard947-PRESSURE GLAUCOMA
TABLE 1. Univariate Analysis of Ocular and Systemic Risk Factors for Occurrence of Disc Hemorrhage in Treated Low-Pressure
Glaucoma Patients
Variables Hazard Ratio
95% Confidence Interval
P ValueMinimum Maximum
Randomization to brimonidine 0.2% 0.607 0.228 1.618 .319
Age (per year) 1.005 0.962 1.048 .825
Systemic arterial hypertension 1.115 0.440 2.825 .819
Diabetes mellitus 0.998 0.229 4.348 .997
History of migraine 4.371 1.431 13.333 .01
History of Raynaud phenomenon 1.902 0.551 6.579 .309
Use of systemic b-blockers 1.351 0.391 4.673 .634
Spherical equivalent (per diopter) 1.051 0.889 1.244 .56
Central corneal thickness (per mm) 1 0.988 1.014 .897
Vertical cup-to-disc ratio (per 0.1 unit) 0.212 0.01 4.464 .319
Narrower neuroretinal rim width at baseline 2.046 0.794 5.291 .138
Mean follow-up intraocular pressure (per mm Hg) 0.906 0.728 1.127 .374
Mean follow-up systolic blood pressure (per mm Hg) 1.041 1.001 1.081 .043
Mean follow-up diastolic blood pressure (per mm Hg) 1.058 0.980 1.14 .145
Mean follow-up heart rate (per beats/minute) 0.99 0.936 1.047 .729
Mean follow-up ocular perfusion pressure (per mmHg) 1.129 1.024 1.244 .015
Statistically significant P Values are in bold.
TABLE 2. Multivariate Analysis of Ocular and Systemic Risk Factors in the Model 1 for Occurrence of Disc Hemorrhage in Treated
Low-Pressure Glaucoma Patients
Variables Hazard Ratio
95% Confidence Interval
P ValueMinimum Maximum
Randomization to brimonidine 0.2% 0.298 0.08 1.115 .072
Gender (female) 1.48 0.415 5.263 .546
History of migraine 5.737 1.46 22.727 .012
History of Raynaud phenomenon 3.476 0.837 14.493 .086
Use of systemic b-blockers 5.585 1.119 27.778 .036
Narrower neuroretinal rim width at baseline 2.91 1.008 8.403 .048
Mean intraocular pressure (per mm Hg) 0.84 0.654 1.079 .172
Mean systolic blood pressure (per mm Hg) 1.06 1.009 1.1122 .02
Mean diastolic blood pressure (per mm Hg) 1.054 0.967 1.151 .228
Mean follow-up heart rate (per beats/minute) 0.962 0.887 1.042 .34
Statistically significant P Values are in bold.to the number of eyes experiencing disc hemorrhage, 12
(8.6%) of 138 eyes in the timolol group had at least 1
disc hemorrhage, compared with 6 (5.2%) of 115 eyes
in the brimonidine group (P ¼ .33, Fisher exact test).
Recurrent disc hemorrhage occurred in 10 (83.3%) of
12 timolol eyes and in 3 (50%) of 6 brimonidine eyes
(P ¼ .26). With regard to the number of patients experi-
encing disc hemorrhage, 10 (14.4%) of 69 patients in the
timolol group had at least 1 disc hemorrhage, compared
with 5 (8.6%) of 58 patients in the brimonidine group
(P ¼ .41). Recurrent disc hemorrhage occurred in 9948 AMERICAN JOURNAL OF(90%) of 10 timolol patients and in 2 (40%) of 5 brimo-
nidine patients (P ¼ .07).
Univariate analysis showed that a history of migraine
(hazard ratio [HR], 4.371; P¼ .01), low systolic blood pres-
sure (HR, 1.041; P ¼ .043), and low mean arterial ocular
perfusion pressure (HR, 1.129; P ¼ .015) were significant
risk factors for the occurrence of disc hemorrhage. In addi-
tion, we observed that treatment randomization to either
timolol or brimonidine did not influence these outcomes
significantly (for timolol: HR, 1.64; P ¼ .33). These results
are summarized in Table 1.MAY 2014OPHTHALMOLOGY
TABLE 3. Multivariate Analysis of Ocular and Systemic Risk Factors in the Model 2 for Occurrence of Disc Hemorrhage in Treated
Low-Pressure Glaucoma Patients
Variables Hazard Ratio
95% Confidence Interval
P ValueMinimum Maximum
Randomization to brimonidine 0.2% 0.411 0.135 1.247 .116
Gender (female) 1.948 0.615 6.173 .257
History of migraine 4.716 1.263 17.544 .021
History of Raynaud phenomenon 2.641 0.663 10.526 .169
Use of systemic b-blocker 4.302 0.943 19.608 .06
Narrower neuroretinal rim width at baseline 2.881 1.038 8 .042
Mean follow-up ocular perfusion pressure (per mmHg) 1.172 1.044 1.316 .007
Statistically significant P Values are in bold.In the multivariate analysis, our first model (model 1)
demonstrated that a history of migraine (HR, 5.737; P ¼
.012), narrower neuroretinal rim width at baseline (HR,
2.91; P ¼ .048), use of systemic b-blockers (HR, 5.585;
P ¼ .036), and low mean systolic blood pressure during
follow-up (HR, 1.06; P ¼ .02) were significant and inde-
pendent risk factors for the occurrence of disc hemorrhage
(Table 2). In model 2, we observed that a history of
migraine (HR, 4.716; P ¼ .021), narrower neuroretinal
rim width at baseline (HR, 2.881; P ¼ .042), and low
mean arterial ocular perfusion pressure during follow-up
(HR, 1.172; P ¼ .007) were relevant and independent
risk factors for episodes of disc hemorrhage in low-
pressure glaucoma (Table 3). Consistent with the univari-
ate analysis, treatment randomization did not affect the
occurrence of disc hemorrhage in model 1 (for timolol:
HR, 3.59; P ¼ .056) or in model 2 (for timolol: HR, 2.53;
P ¼ .082; see Tables 2 and 3).DISCUSSION
ALTHOUGH DISC HEMORRHAGE OCCURRENCE IS NOT A
pathognomonic sign of progression in glaucoma—because
not all eyes with disc hemorrhage progress—the strong
association between them should be considered when
discussing risk factors for one or the other, because they
often overlap. In addition, it remains unclear whether risk
factors described for VF progression11,15 are the same as
those that contribute to glaucomatous structural changes
over time. This study aimed to identify ocular and
systemic risk factors for the occurrence of disc hemorrhage
in the Low-Pressure Glaucoma Treatment Study popula-
tion.We found that a history of migraine, low systolic blood
pressure, low mean arterial ocular perfusion pressure, use of
systemicb-blockers, and narrower neuroretinal rim width at
baseline constituted independent risk factors. Among these
predictors, a history of migraine, low systolic blood pressure,
and use of systemic b-blockers are IOP-independentVOL. 157, NO. 5 DISC HEMORRHAGE IN LOWparameters, which supports the contribution of mechanisms
other than or in addition to IOP in the pathogenesis of disc
hemorrhage in low-pressure glaucoma.8,16,19,38
Our findings are, at least in part, consistent with previous
studies.35,36 In a study of 432 primary open-angle glaucoma
eyes, Jonas and associates demonstrated that a smaller optic
disc neuroretinal rim area was a morphologic parameter
associated with the occurrence of disc hemorrhage and sug-
gested that disc hemorrhages are seen more often in eyes
with thinner rims.35 In our study, neuroretinal rim damage
at baseline also was an independent risk factor for disc hem-
orrhage in low-pressure glaucoma, and its presence
increased the risk of disc hemorrhage detection by approx-
imately 3-fold in both multivariate models. In another
study, Kim and associates showed that systemic blood pres-
sure plays a role in the onset of disc hemorrhage.36 Howev-
er, unlike our findings, they found that the only significant
risk factor for disc hemorrhage occurrence in low-pressure
glaucoma was systemic hypertension. This apparent
discrepancy between studies could be explained by (1) dif-
ferences regarding study design, because those investigators
applied a retrospective analysis; (2) factors related to
genetics—European ancestry was predominant in our study
compared with Asian ancestry in theirs; and (3) the fact
that being diagnosed (and treated) with systemic hyperten-
sion does not preclude patients from actually having low
blood pressure during follow-up, particularly nighttime
dips. It is noteworthy that in their study, blood pressure
readings were not collected during follow-up as we did.
Thus, they might have overlooked the blood pressure-
lowering effect of the antihypertensive medications in
those patients. Overtreatment of systemic hypertension
may lead to a series of complications including stroke and
reduction of ocular perfusion pressure.39–41 Moreover,
treatment for systemic hypertension has been reported as
a risk factor for incident glaucoma42 and VF progression
in established disease.5,15
The Early Manifest Glaucoma Trial, which included
patients with newly diagnosed glaucoma ranging from
low to high IOP, found that female gender, myopia, and949-PRESSURE GLAUCOMA
lower baseline or follow-up IOP were independent risk fac-
tors for disc hemorrhage detection.27 The Early Manifest
Glaucoma Trial investigators did not investigate these
risk factors further in the subgroup of eyes with low-
pressure glaucoma. In our study, these variables did not
reach statistical significance.
The association between low-pressure glaucoma and a
history of migraine headache has been suggested in previ-
ous publications.43,44 Corbett and associates found that
44% of their low-pressure glaucoma sample reported a
history of migraine.43 In a questionnaire-based study
that investigated migraine in low-pressure glaucoma,
high-pressure primary open-angle glaucoma, ocular hyper-
tensive, and normal subjects, the low-pressure glaucoma
group had a greater prevalence of migraine than the other
groups.44 Moreover, in the Collaborative Normal Tension
Glaucoma Study,11 migraine was a risk factor for functional
progression in patients with low-pressure glaucoma. In the
present study, we demonstrated that migraine is a predictor
for the occurrence of disc hemorrhage. Migraine is associ-
ated with transient cerebral vasospastic episodes that can
result in impairment in the mechanisms of autoregu-
lation of blood flow in the central nervous system.45,46
Neuroimaging studies suggest that silent cerebral infarct,
which is an infarct in the brain incidentally detected in
individuals without clinical neurologic signs, can be found
in patients with migraine46 and low-pressure glaucoma.47,48
In addition, low-pressure glaucoma patients with silent
cerebral infarct had faster rates of VF deterioration than those
without, suggesting the role of ischemic injury in glaucoma
progression.48 Autoregulation may be inefficient in patients
with glaucomatous optic neuropathy and may result in vary-
ing degrees of ischemia at the optic nerve.49 This could pre-
dispose one to microinfarction at the optic nerve head
and the occurrence of disc hemorrhage.16,50 Therefore,
those studies support our results, because migraine seems
to be a clinical marker of an impaired microvascular
autoregulation. One limitation of the present study is that
the diagnosis of migraine was based on self-report during
standardized interview. Therefore, the true number of
patients with this condition in our sample is unknown, which
could have influenced its statistical significance.
In one of our models, use of systemic b-blockers was
a predictor of disc hemorrhage detection. Systemic
b-blockers are known to be less effective than other antihy-
pertensive medications in decreasing the rates of ischemic
events, such as myocardial infarction and stroke.51 Thus,
one could hypothesize that b-blockers would not offer
enough protection to the optic nerve head tissues regarding
ischemia-related events and may predispose patients to the
occurrence of disc hemorrhage. Further, overtreatment for950 AMERICAN JOURNAL OFsystemic hypertension increases the risk of coronary
ischemia and mortality,39–41 and likewise could be
deleterious to the optic nerve head by decreasing the
mean arterial ocular perfusion pressure. An alternative
explanation is that systemic b-blocker use contributed to
a reduced IOP-lowering efficacy in eyes receiving topical
timolol 0.5%, predisposing them to disc hemorrhage.
Nevertheless, it is important to stress that our study did
not aim to investigate the specific role of systemic antihy-
pertensives on disc hemorrhage occurrence, because infor-
mation regarding the dosage, posology, duration of
treatment, and 24-hour blood-pressure monitoring was
not collected as part of the Low-Pressure Glaucoma Treat-
ment Study protocol. Future studies are warranted to assess
these variables, how they affect the 24-hour blood-pressure
pattern, and the risk of progression in low-pressure glau-
coma.
Although low-pressure glaucoma patients treated with
timolol 0.5% progressed faster than those treated with
brimonidine 0.2%,14,15 we found no difference in the
frequency of disc hemorrhage detection in the present
analysis. Although not statistically significant, there were
more disc hemorrhage events in eyes receiving timolol
compared with eyes receiving brimonidine. Our study
may have been underpowered to detect differences
regarding the frequency of disc hemorrhage, and this
should be taken into consideration when interpreting our
results. The Low-Pressure Glaucoma Treatment Study
sample size calculation was aimed to test differences in rates
of progression, and not disc hemorrhage occurrence, and
hence the present ancillary analysis may not have had suf-
ficient statistical power for disc hemorrhage detection. It is
also possible that we would have detected a difference in
disc hemorrhage occurrence between the 2 treatments in
a longer study. The mean follow-up in the Low-Pressure
Glaucoma Treatment Study was only 40.6 6 12 months,
because of higher-than-expected dropout resulting from
adverse reactions to the medication. A study with larger
sample size, longer follow-up time, and more frequent optic
disc photography would be necessary to prove or refute the
role of the type of medication on disc hemorrhage occur-
rence and recurrence.
In summary, we demonstrated that a history of migraine,
narrower neuroretinal rim width at baseline, low systolic
blood pressure or low mean arterial ocular perfusion pres-
sure, and use of systemic b-blockers are risk factors for the
occurrence of disc hemorrhage in treated low-pressure glau-
coma patients. The finding that variables unrelated to IOP
were associated with the occurrence of disc hemorrhage un-
derscores the role of IOP-independent factors in the path-
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